Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Cancer
- Disease
- Dermatology
- Therapeutic
- Personal Care Products
- Pharmaceuticals
- Hair loss
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 218779
IPSCIO Record ID: 256952
IPSCIO Record ID: 26963
IPSCIO Record ID: 209489
Intellectual Property and Intellectual Property Rights means the trade marks and Patent Rights. The patent information is referred to as Solarase I, II, and III.
Solaraze Gel is a treatment for the chronic skin condition actinic keratosis.
Actinic keratosis is a pre-cancerous patch of thick, scaly, or crusty skin.
IPSCIO Record ID: 279348
— during the Research Term, a non-exclusive, worldwide, license, without the right to sublicense, under the Licensor Technology solely to perform Licensees obligations under the Research Plan; and
— an exclusive, worldwide license, including the right to sublicense, under the Licensor Technology and Licensors interest in the Joint Patent Rights, to develop, make, have made, use, sell, have sold, offer for sale and import Selected Compounds and Products solely in the Licensee Field.
Product shall mean any final dosage form of a pharmaceutical product containing a Selected Compound for use in the Licensee Field.
Licensor Field shall mean the local administration of Excluded Compounds for
— the treatment or prevention of cardiovascular diseases and disorders in humans, including but not limited to the use of an Excluded Compound coated on a cardiovascular stent and ex vivo use of Excluded Compounds for the preparation of cells to be used in cell therapy applications; and/or any other indication in humans (excluding any indication within the Licensee Field) to which Licensor obtains rights from Third Party after the Effective Date; and/or
— the Veterinary Field. Veterinary Field shall mean Topical Application of a Licensed Compound for the treatment or prevention of any skin disease or disorder in animals, excluding humans.
Licensee Field shall mean the Topical Application of a Selected Compound or Product for the promotion of hair growth in humans (Hair Growth lndications); and/or any other indication in which Topical Application is used in humans – each, a Skin-Related Indication.
IPSCIO Record ID: 299247
— an exclusive license, with right to sublicense through one or more tiers, under the Licensed Patent Rights to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import and have imported Products in the Field.
— an exclusive license, with right to sublicense through one or more tiers, under the Know-How, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import and have imported Products in the Field and a nonexclusive license to any other know-how existing on the Closing Date and provided to Licensee which is useful to develop or commercialize the Products in the Field.
The Assigned Patent Rights and Licensed Patent Rights include any prodrug or any hydrate, solvate, conjugate, salt, ester, stereoisomer or polymorph of such compound or prodrug.
— the treatment, topically or systemically, of diseases of the cervix or vaginal tract caused by human papilloma virus (HPV) infection, including cervical high risk·HPV infection and cervical dysplasia, and the treatment of cervical malignancy by topical application to the cervix, but not including systemic treatments of cervical malignancy;
— any use of imiquimod, 848 (resiquimod}, 850 (sotirimod), and the alkyl ureas S-32913 and S-33005, including any acid, ester, salt, amide, prodrug, polymorph, enantiomer or isomer thereof, and any pharmaceutical product containing such compounds, in the Topical Field, which means the treatment, mitigation, or prevention of a disease or condition by topical application (e.g., dermatological, pulmonary or vaginal) of the drug to the skin or mucosa (e.g., bronchialand vaginal tissue) of a patient by, for example, but not limited to, gels, creams, ointments, foams, lotions, salves, roll-ons, powders, sprays, or inhalants, like aerosols such as for asthma and allergic rhinitis;
— marketing the 3MIRM Compounds 852 (N-[4-(4-amino-2-ethyl-1Himidazo[4;5 c]quinoliri-1-yl)butyl]methanesulfonamide) and/or 854 (N-{2-[4-amino-2 ( ethoxymethyl)-1 H-imidazo[ 4, 5-c]quinolin-1-yl]-1 , 1-d imethylethyl}methanesulfonamide) (including any acid, ester, salt, amide, pro-drug, polymorph, enantiomer or isomer thereof, and.any pharmaceutical product containing such compounds) for the indications of genital warts, common warts, basal cell carcinoma, actinic keratosis, tattoo removal, or photoaging; and
— any use of the 3M Compounds as a Vaccine Adjuvant.
